Related Experiment Videos
Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases
Nigel H Greig1, Tony Giordano, Xiaoxiang Zhu
1Drug Design and Development Section, Lab. of Neurosciences, Intramural Research Prog., National Inst. on Aging, National Inst. of Health, 5600 Nathan Shock Dr., Baltimore, MD 21224, USA. GreigN@vax.grc.nia.nih.gov.
Acta Neurobiologiae Experimentalis
|June 12, 2004
Summary
New drug analogs effectively inhibit tumor necrosis factor-alpha (TNF-alpha), a key inflammatory molecule in neurodegenerative diseases. These novel compounds show improved potency and brain penetration compared to existing therapies.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Tumor necrosis factor-alpha (TNF-alpha) overproduction is implicated in neurodegenerative and systemic inflammatory diseases.
- Current TNF-alpha inhibitors like Remicade and Enbrel are large, injectable, and have limited brain penetration.
- Thalidomide, a known drug, inhibits TNF-alpha and is used clinically, serving as a basis for developing improved analogs.
Purpose of the Study:
- To discover novel, potent isosteric analogs of thalidomide with enhanced lipophilicity for improved brain penetration.
- To evaluate the TNF-alpha inhibitory activity of these novel analogs.
Main Methods:
- Structural modification of thalidomide to create new analogs.
- Evaluation of TNF-alpha inhibitory activity in lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs).
- Quantification of cell viability to distinguish TNF-alpha inhibition from cytotoxicity.
- Assessment of the mechanism of action using luciferase assays to determine effects on TNF-alpha mRNA stability via the 3'-untranslated region (UTR).
Main Results:
- Several novel analogs demonstrated potent inhibition of TNF-alpha secretion, surpassing thalidomide's efficacy.
- The inhibition of TNF-alpha occurred via a post-transcriptional mechanism, specifically by decreasing TNF-alpha mRNA stability.
- The 3'-UTR of human TNF-alpha was identified as the target region for this mRNA destabilization.
Conclusions:
- Novel thalidomide analogs exhibit potent TNF-alpha inhibitory activity.
- These analogs possess improved properties for potential therapeutic applications, particularly in conditions affecting the brain.
- The identified mechanism of action provides a basis for further drug development targeting TNF-alpha-mediated inflammation.